MGMT Recombinant Monoclonal Antibody

1. MGMT Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas. PMID: 30343277
2. In patients with neuroendocrine neoplasms, response to therapy, progression free survival and overall survival was correlated to MGMT promoter methylation status PMID: 29150792
3. The first evidence for non-repair functions of MGMT in cell cycle and highlight the involvement of PCNA in MGMT downregulation, with p21 attenuating the process. PMID: 29510343
4. The methylation of the MGMT promoter is uncommon, or occurs at a low frequency in meningiomas. There is no convincing rationale to test such tumors for their MGMT methylation status in a clinical setting PMID: 30194078
5. Data revealed that MGMT gene methylation was higher in non-small-cell lung carcinoma (NSCLC) tissue samples than normal. Also advanced stage NSCLC patients showed higher methylation than early stage patients without impacting patients survival. These results provided clear evidence about the association of MGMT hypermethylation with increased risk of NSCLC. [review] PMID: 29362385
6. There is no difference in the expression of Integrin alphavbeta3 between tumor samples from glioblastomas patients with methylated or unmethylated promoter regions in the (6)O-methylguanine methyltransferase (MGMT). PMID: 29882028
7. Germline variants in MGMT gene are associated with prostate cancer. PMID: 29298992
8. Promoter Hypermethylation of MGMT Gene is associated with Colorectal Cancer. PMID: 29801405
9. Our study confirmed that the independent prognostic role of MGMT methylation status. An average level of methylation between all investigated CpGs of 9% may help discriminating between methylated and unmethylated tumors. PMID: 29521523
10. results indicated that the MGMT rs12917 TT genotype increases the risk of Head and neck squamous cell carcinoma PMID: 29370316
11. Strong MGMT expression was associated with survival in pancreatic ductal adenocarcinoma PMID: 29735403
12. MGMT promoter methylation may be correlated with the tumorigenesis of ovarian cancer. It was associated with tumor histotypes, but not correlated with clinical stage and tumor grade. PMID: 29195029
13. use a compendium of brain MRI scans collected from The Cancer Imaging Archive (TCIA) combined with methylation data from The Cancer Genome Atlas (TCGA) to predict the methylation state of the MGMT regulatory regions in glioblastoma patients PMID: 29218894
14. In summary of this results and the published data clearly indicate that MGMT promoter methylation is a rare event in DMG patients supporting the idea that analyzing the MGMT promoter status would only be recommended in H3 K27M-wildtype GBM. PMID: 29246238
15. The changes in MGMT expression reflect the impairment of DNA repair, which probably serves as a stage in the development and progression of endometriosis. PMID: 29308563
16. MGMT methylation was observed in 37% of cases with primary CNS diffuse large B-cell lymphoma PMID: 28856744
17. Methylguanine methyltransferase (MGMT) is a key gene that encodes for a protein that repairs DNA. PMID: 28785873
18. Study provides evidence that low-expression of TET1 in oral squamous cell carcinoma (OSCC) stem cells may stimulate MGMT promoter methylation, while inhibiting MGMT mRNA expression, which ultimately strengthens the sensitivity of OSCC stem cells in regards to chemotherapeutics. PMID: 28643947
19. High MGMT expression is associated with glioblastoma multiforme resistance to temozolomide PMID: 27595933
20. This study shows that when cell death and cell cycle arrest pathways are inhibited, p53 can still mediate MGMT-dependent repair, to promote cell survival upon DNA damage. PMID: 28753207
21. Data suggest that MGMT promoter methylation could be an important factor in determining which melanoma patients should receive melphalan regional chemotherapy. PMID: 28486243
22. MGMT promoter methylation may be correlated with esophageal cancer carcinogenesis and could be associated with age, lymph node status, and clinical stage. PMID: 29258097
23. DNA promoter hypermethylation and gene expression of MGMT may associate with recursive mutagenesis and is a promising biomarker for OSCC prediction. PMID: 28458179
24. Results show that folate concentrations >45.3 nmol/L increased the risk of methylation in specific CpG sites of MGMT. PMID: 28748002
25. miR-198 decreased the protein expression of MGMT through inhibiting the translation of the MGMT mRNA into the MGMT protein in vitro and in vivo. Results showed that MiR-198 induces temozolomide chemosensitivity in glioblastoma by targeting MGMT and that miR-198 may be used as a new diagnostic marker and therapeutic target for glioblastoma in the future. PMID: 28425046
26. Alkylating agents have high activity in well-differentiated pancreatic neuroendocrine tumors regardless of MGMT status. PMID: 28609363
27. MGMT gene variants are associated with temozolomide myelotoxicity and glioma risk. PMID: 28436299
28. Deficient MGMT status in pancreatic neuroendocrine tumors, determined by loss of protein expression or by the presence of MGMT gene promoter methylation is not associated with a better response to temozolomide-based chemotherapy. PMID: 28328619
29. MGMT promoter methylation in Epstein-Barr virus-associated oral squamous cell carcinomas PMID: 28573642
30. Data show that O(6)-methylguanine-DNA methyltransferase (MGMT) Leu84Phe was significantly related to temozolomide (TMZ) resistance and the prognosis of patients with malignant gliomas. PMID: 28409559
31. MGMT promoter methylation was determined by methylation-specific polymerase chain reaction PMID: 27409829
32. MGMT methylation is a prognostic factor in newly diagnosed glioblastoma. In this study, we evaluated the rate of change of MGMT methylation during the clinical course of the disease, and we found a significant concordance between the first and the second MGMT methylation assessments, with MGMT methylation being stable in 75% of the cases PMID: 28275120
33. Findings show the cell-context dependent effects of PRIMA-1MET irrespective of p53 status and suggest the role of O6-methylguanine-DNA methyltransferase (MGMT) as a potential molecular target of PRIMA-1MET in MGMT-positive glioblastoma stem cell (GSCs). PMID: 27533246
34. MGMT methylation assay, of which PSQ appeared to be the best, could improve the predictive power for Glioblastoma patients with MGMT IHC- tumors PMID: 27153440
35. Both blood and tumor tissue MGMT and ERCC1 methylation were associated with cancer rectum. PMID: 29080834
36. MGMT promoter methylation may be an early biomarker for the diagnosis of breast cancer (Meta-Analysis) PMID: 28848211
37. Low MGMT expression assessed by immunochemistry in temozolomide-treated patients with pancreatic neuroendocrine tumors is associated with radiological objective response and increased progression-free survival. PMID: 27353036
38. Rs16906252C>T is associated with elevated risk for MGMT-methylated colorectal cancer. PMID: 27267851
39. Treatment of metastatic colorectal cancer (mCRC) with temozolomide driven by MGMT promoter hypermethylation in AT samples did not provide meaningful PFS rate at 12 weeks. This biomarker changed from AT to BT, indicating that testing BT biopsy or plasma is needed for refined target selection PMID: 26916096
40. the MGMT promoter homozygous rs1625649 (AA genotype) was found to correlate with a better PFS in patients with MGMT methylated glioblastoma PMID: 29036186
41. Using a large cohort of newly diagnosed adult gliomas with precise clinical information, study demonstrated that molecular classification using IDH and TERT statuses is a strong prognostic marker of adult gliomas. Results emphasize the importance of combining molecular markers such as IDH, 1p/19q, TERT, and MGMT for accurate molecular diagnosis, prognostication, and the choice of treatment. PMID: 27503138
42. Review/Meta-analysis: MGMT promoter methylation was associated with longer overall survival in glioblastoma patients. PMID: 28266716
43. Low MGMT expression is associated with pituitary adenoma tumor recurrence. PMID: 28152515
44. According to our results, albeit aberrant methylation of MGMT gene promoter can be observed in in vitro propagated Merkel cell carcinoma (MCC)cell lines, it seems to be absent or very rare in MCC lesions in situ PMID: 28405827
45. A novel recursive partitioning analysis classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era PMID: 28302331
46. Nitrogen mustard-induced MGMT-DNA crosslinking in 16HBE cells. PMID: 28720507
47. Results show that allelic frequencies of the MGMT promoter region locus rs1625649 between patients and healthy control groups were statistically significantly different suggesting an association with the occurrence of laryngeal cancer. PMID: 28739733
48. Combination of MGMTmethylation/IDH1 mutation is associated with considerably longer overall survival of chemoradiotherapy-treated glioblastoma patients. PMID: 27526690
49. MGMT protein expression assessed by immunohistochemistry did not play an important role as a predictive marker for alkylating agents. PMID: 28476818
50. Glioblastoma patients with high IFIT1 and low MGMT expression have an improved prognosis. PMID: 26980050

Show More

Hide All

HGNC: 7059

OMIM: 156569

STRING: 9606.ENSP00000302111

UniGene: Hs.501522